Results 151 to 160 of about 20,669 (341)

Convergent approach towards ADP‐ribosylated‐peptides via a chemoselective phosphate condensation

Chemistry – A European Journal, Accepted Article.
The preparation of well‐defined ADP‐ribosylated peptides is essential for studying the functional implications of this post‐translational modification. While methodologies exist for the chemical synthesis of short oligo‐ADPr fragments and mono‐ADP‐ribosylated peptides separately, combining the two distinct chemistries, required to assemble them, has ...
Sven Wijngaarden, Femke L. A. M. van der Heijden, Cindy J. Bogaart, Maria Siskou, Ioanna Tsoumani, Daisy J. Robinson, Gijsbert A van der Marel, Jeroen D. C. Codée, Herman S. Overkleeft, Dmitri Filippov   +9 more
wiley   +1 more source

THE ENZYMATIC SYNTHESIS AND PROPERTIES OF RIBULOSE 1,5-DIPHOSPHATE

, 1956
B.L. Horecker, Jerard Hurwitz, Arthur Weissbach   +2 more
openalex   +1 more source

Pyrophosphorolysis and enzymic synthesis of cytidine diphosphate glycerol and cytidine diphosphate ribitol [PDF]

, 1962
DRD SHAW
openalex   +1 more source

The plant Nudix hydrolase family. [PDF]

, 2008
Nudix hydrolases are a family of proteins defined by a conserved amino-acid sequence GX(5)-EX(7)REUXEEXGU, where U is a hydrophobic residue. These enzymes are widely distributed among all classes of organisms and catalyze, with varying degrees of ...
Kraszewska, Elzbieta
core  

First‐in‐Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN‐3143, a Novel Inhibitor of Mono‐Adenosine Diphosphate Ribosyltransferase‐PARP14

Clinical Pharmacology in Drug Development, EarlyView.
Abstract RBN‐3143 is an inhibitor of PARP14 in development for inflammatory diseases. Multiple assessments were conducted to evaluate the clinical pharmacology properties of RBN‐3134. A randomized, double‐blind, placebo‐controlled study assigned healthy volunteers (HVs) to single ascending doses (SADs) (25‐1000 mg) or multiple ascending doses (MADs ...
Thomas M. Polasek, Alexandra Cole, Viviana Bozón, Erika Manyak, Jonathan Novak, Barbara Yang, Briohny A. Johnston, Sudha Parasuraman, Kushal J. Paneliya, Virna Schuck   +9 more
wiley   +1 more source

THE ISOLATION OF URIDINE DIPHOSPHATE DERIVATIVES OF d-GLUCOSE, d-GALACTOSE, d-XYLOSE, AND l-ARABINOSE FROM MUNG BEAN SEEDLINGS

, 1956
Victor Ginsburg, P.K. Stumpf, W. Z. Hassid   +2 more
openalex   +1 more source

Фосфати Zn²⁺, Cu²⁺ як бактерицидні наповнювачі склоемалевих покриттів [PDF]

, 2007
В статті розглянуто перспективність використання фосфатів Zn²⁺, Cu²⁺ як бактерицидних наповнювачів склоемалевих покриттів. Описано синтез дифосфатів Zn²⁺, Cu²⁺ та дослідено їх склад з використанням диференціально-термічного та рентгенофазового аналізу ...
Брагіна, Людмила Лазарівна, Васютін, Ф. А., Покроєва, Яна Олександрівна, Саввова, Оксана Вікторівна, Соболь, Н. П., Шалигіна, Оксана Володимирівна   +5 more
core  

Microtracer‐Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [14C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Berzosertib is a small‐molecule ataxia telangiectasia and Rad3‐related protein inhibitor. To assess the clearance mechanism(s) of berzosertib, a Phase 1, 2‐period, open‐label study was conducted in adults with advanced solid tumors who were treated with a single intravenous dose of 210 mg/m2 berzosertib containing approximately 3 µCi of [14C ...
Jayaprakasam Bolleddula, Holger Scheible, Florian Huber, Annick Seithel‐Keuth, Hanno Schieferstein, Deepthi S. Vagge, Nadra Mammasse, Eva Jaks, Jordi Ferrer, Camilo Moulin, Jennifer Dong, Karthik Venkatakrishnan, Zsuzsanna Papai   +12 more
wiley   +1 more source

A COMPARISON OF THE REACTION KINETICS OF ADENYLIC ACID AND ADENOSINE DIPHOSPHATE WITH THE RESPIRATORY CHAIN

, 1957
Britton Chance
openalex   +1 more source

Inhibition of OATP1B1/3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration

Clinical Pharmacology &Therapeutics, EarlyView.
Atazanavir has been reported to increase total serum bilirubin level up to ninefold. It is widely believed that the observed total bilirubin elevation is primarily due to UGT1A1 inhibition. However, UGT enzymes are well‐known as a low‐affinity and high‐capacity system, and the observed drug–drug interaction mediated by UGTs is usually less than twofold.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source